Barclays PLC Has $3.80 Million Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Barclays PLC lifted its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 22.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 174,855 shares of the company's stock after buying an additional 32,250 shares during the period. Barclays PLC owned about 0.57% of Fulgent Genetics worth $3,800,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in FLGT. Bank of New York Mellon Corp grew its holdings in shares of Fulgent Genetics by 37.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 201,201 shares of the company's stock worth $3,948,000 after purchasing an additional 55,020 shares in the last quarter. Signaturefd LLC boosted its stake in Fulgent Genetics by 103.6% during the second quarter. Signaturefd LLC now owns 2,225 shares of the company's stock worth $44,000 after buying an additional 1,132 shares in the last quarter. nVerses Capital LLC bought a new stake in Fulgent Genetics in the 2nd quarter valued at $43,000. Rhumbline Advisers raised its stake in shares of Fulgent Genetics by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 68,210 shares of the company's stock valued at $1,338,000 after buying an additional 637 shares in the last quarter. Finally, Acuitas Investments LLC acquired a new position in shares of Fulgent Genetics in the 2nd quarter valued at $962,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Fulgent Genetics

In related news, CEO Ming Hsieh sold 2,227 shares of the firm's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $18.26, for a total transaction of $40,665.02. Following the completion of the sale, the chief executive officer now directly owns 703,711 shares of the company's stock, valued at $12,849,762.86. This trade represents a 0.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 3,413 shares of company stock valued at $62,321 in the last ninety days. Insiders own 32.66% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on FLGT. StockNews.com lowered shares of Fulgent Genetics from a "hold" rating to a "sell" rating in a research report on Wednesday, November 27th. Piper Sandler decreased their price objective on Fulgent Genetics from $26.00 to $22.00 and set a "neutral" rating on the stock in a report on Monday, November 11th.

Fulgent Genetics Stock Up 1.4 %

NASDAQ:FLGT traded up $0.25 during trading hours on Monday, reaching $18.59. The company had a trading volume of 251,965 shares, compared to its average volume of 193,618. The stock has a 50-day moving average of $19.45 and a two-hundred day moving average of $20.92. Fulgent Genetics, Inc. has a one year low of $16.56 and a one year high of $30.60. The firm has a market capitalization of $568.61 million, a PE ratio of -3.37 and a beta of 1.42.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.